# NCT04014075 (NCT04014075)

> DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04014075
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Daiichi Sankyo
- Conditions: Adenocarcinoma Gastric Stage IV With Metastases; Adenocarcinoma - GEJ
- Interventions: Trastuzumab deruxtecan
- Enrollment: 79
- Primary outcome: Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma
- Primary outcome: Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Positive Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma

## Commentary we found

- YouTube: 27
- Podcasts: 23
- X threads: 9

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04014075

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04014075", "email": "<work email>"}; the inbox owner confirms by the emailed link.